Launched in 2016, XaTek is an innovative diagnostic solutions company. The company’s platform technology is an in vitro diagnostic global assay for the assessment of any patient’s bleeding profile. This novel technology has the ability to serve the unmet clinical needs for numerous clinical scenarios. The company is initially focused on the factor Xa inhibitor anticoagulants and hemophilia markets. XaTek is currently in the clinical stage of development of its handheld point-of-care device.